Perspective Therapeutics, Inc. Common Stock (CATX)
3.1400
-0.1000 (-3.09%)
Previous Close | 3.240 |
---|---|
Open | 3.230 |
Bid | 3.100 |
Ask | 3.280 |
Day's Range | 3.130 - 3.290 |
52 Week Range | 2.700 - 19.05 |
Volume | 416,805 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 945,087 |
News & Press Releases
![](https://cdn.benzinga.com/files/images/story/2025/01/24/cancer.jpeg?width=1200&height=800&fit=crop)
Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, and anti-tumor activity.
Via Benzinga · January 24, 2025
![](https://www.investors.com/wp-content/uploads/2020/07/Stock-covidtestcar-03-adobe.jpg)
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.
Via Investor's Business Daily · January 17, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 21, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/21/Wall-Street-US-stocks.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 21, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/30/Stein--Switzerland---February-18--2020-N.jpeg?width=1200&height=800&fit=crop)
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via Benzinga · October 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11.png?width=1200&height=800&fit=crop)
Perspective Therapeutics shares are trading lower by 12.9% Thursday morning. The company announced the pricing of an underwritten public offering.
Via Benzinga · January 18, 2024
![](/next-assets/images/schema-image-default.png)
Via Benzinga · October 11, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/11/bz-pharma-briefs.jpeg?width=1200&height=800&fit=crop)
Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals.
Via Benzinga · October 11, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
CATX stock results show that Perspective Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 12, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/nvda_nvidia1600-2-1024x576.png)
Given its performance in 2024, there are very few stocks outperforming Nvidia this year. Here are three of them.
Via InvestorPlace · July 25, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/14/Penny-stock-tips-cover.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://www.marketbeat.com/logos/articles/med_20240520081410_insider-trading-is-good-news-for-these-stocks.jpg)
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
Via MarketBeat · May 20, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
CATX stock results show that Perspective Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/Bull-and-bear-stock-market-index_11.jpeg?width=1200&height=800&fit=crop)
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.
Via Benzinga · March 28, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 15, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 9, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 7, 2024
![](https://cdn.benzinga.com/files/images/story/2024/02/02/image44.jpg?width=1200&height=800&fit=crop)
The Dow Jones index closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · February 2, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/31/image38.jpeg?width=1200&height=800&fit=crop)
The Dow Jones index closed higher by more than 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · January 31, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/29/image33.jpeg?width=1200&height=800&fit=crop)
The Dow Jones index closed higher by around 60 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · January 29, 2024